ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 94 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2018. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $91,000 | -48.3% | 44,300 | -5.6% | 0.04% | -37.9% |
Q4 2021 | $176,000 | -28.2% | 46,931 | -0.9% | 0.07% | -38.9% |
Q3 2021 | $245,000 | +15.6% | 47,350 | -5.0% | 0.11% | +24.1% |
Q2 2021 | $212,000 | -45.5% | 49,819 | -32.0% | 0.09% | -47.0% |
Q1 2021 | $389,000 | +0.3% | 73,237 | +1.8% | 0.16% | +1.9% |
Q4 2020 | $388,000 | +57.1% | 71,954 | +132.0% | 0.16% | +23.8% |
Q3 2020 | $247,000 | -30.0% | 31,009 | -12.0% | 0.13% | -22.2% |
Q2 2020 | $353,000 | +61.9% | 35,241 | -30.4% | 0.17% | -64.0% |
Q1 2019 | $218,000 | -34.9% | 50,655 | -13.0% | 0.46% | +714.0% |
Q4 2018 | $335,000 | -34.3% | 58,223 | +54.8% | 0.06% | +7.5% |
Q3 2018 | $510,000 | -34.1% | 37,603 | -42.3% | 0.05% | -92.3% |
Q2 2018 | $774,000 | +307.4% | 65,221 | +141.8% | 0.68% | +643.5% |
Q3 2016 | $190,000 | -13.6% | 26,974 | 0.0% | 0.09% | -43.6% |
Q2 2016 | $220,000 | -3.9% | 26,974 | -4.3% | 0.16% | -48.3% |
Q1 2016 | $229,000 | – | 28,182 | – | 0.32% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Syncona Portfolio Ltd | 1,377,294 | $5,165,000 | 4.93% |
Long Focus Capital Management, LLC | 4,429,491 | $9,125,000 | 1.17% |
Endurant Capital Management LP | 2,160,890 | $4,451,000 | 1.17% |
NEA Management Company, LLC | 17,082,611 | $35,190,000 | 1.02% |
Matrix Capital Management Company, LP | 38,974,185 | $80,287,000 | 0.96% |
Key Client Fiduciary Advisors, LLC | 420,447 | $866,000 | 0.68% |
ACT CAPITAL MANAGEMENT, LLC | 90,000 | $185,000 | 0.20% |
DAFNA Capital Management LLC | 351,064 | $723,000 | 0.19% |
PFM Health Sciences, LP | 2,374,674 | $4,892,000 | 0.18% |
Rock Springs Capital Management LP | 2,297,194 | $4,732,000 | 0.12% |